Education
About Us
Working with TipRanks
Follow Us
Zomedica (ZOMDF)
OTHER OTC:ZOMDF
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
>-0.01Last Year’s EPS
>-0.01Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: 25.00%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
Zomedica's earnings call highlighted strong revenue growth, especially in the diagnostics segment, and successful international expansion. However, these positives were countered by significant challenges, including the delisting from the NYSE and an increased net loss. The company's strong liquidity position and product innovation are promising, but these are tempered by market and operational challenges.Company Guidance
During the Zomedica Fourth Quarter 2024 financial results conference call, CEO Larry Heaton highlighted the company's achievements, including record revenues for the quarter at $7.9 million, marking 8% year-over-year growth. This contributed to a full-year revenue of $27.3 million, demonstrating strong performance in both the therapeutic devices and diagnostics segments. Heaton emphasized the success of their products, such as TRUFORMA and VetGuardian, which saw year-over-year growth of 65% and 95%, respectively. Additionally, the company maintained a healthy gross margin of 70.3%, exceeding the target range. Zomedica's liquidity stood strong with over $71 million, and the company reported a net loss of $7.2 million for the quarter. Heaton addressed concerns about the recent delisting from the NYSE American Exchange, explaining the transition to the OTCQB market and affirming the company's commitment to continue driving growth and achieving profitability.Record Quarterly Revenue
Zomedica achieved a record quarterly revenue of $7.9 million for Q4 2024, reflecting an 8% growth over the prior year quarter.
Significant Growth in Diagnostics Segment
The Diagnostics segment saw a 109% year-over-year increase driven by the growing adoption of TRUFORMA assays and contributions from TRUVIEW and VetGuardian product lines.
International Expansion
Zomedica expanded its global reach by obtaining CE marking for multiple products and signing strategic partnerships with leading distributors in Europe, the Middle East, and other markets, opening up new revenue opportunities.
Launch of New Products
Multiple new products and innovations were launched, including new TRUFORMA assays, the Vetigel Hemostatic Gel, and enhancements to the TRUVIEW platform.
Strong Liquidity Position
The company reported having over $71 million in liquidity with no debt, indicating a strong financial base.
---
ZOMDF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZOMDF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $0.04 | $0.05 | +25.00% |
| Nov 07, 2024 | $0.12 | $0.12 | 0.00% |
| Aug 14, 2024 | $0.16 | $0.15 | -6.25% |
| May 09, 2024 | $0.16 | $0.14 | -12.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zomedica (ZOMDF) report earnings?
Zomedica (ZOMDF) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Zomedica (ZOMDF) earnings time?
Zomedica (ZOMDF) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZOMDF EPS forecast?
ZOMDF EPS forecast for the fiscal quarter 2025 (Q1) is >-0.01.
---